Prostate cancer is one of the popular male genital malignancies worldwide. Several studies have interested on the impact of AMACR expression as indicative and prognostic marker for prostate cancer. Many researches focused on Gleason's score, PSA and bone scintigraphy in diagnosis and prognosis of prostate cancer. Our aim is to explore the immune histo-chemical expression of AMACR as additional prognostic and predictive marker in prostate cancer. Material and Methods: Immune histo-chemical staining of AMACR on tissue core biopsies of 49 patients with advanced prostatic cancer and evaluated its expression in relation to Gleason's score, initial PSA level, nadirPSA level and bone scan as well as biochemical failure to androgen deprivation therapy. Results: we found statistically significant relation between high AMACR expression and high Gleason's score. Patients with high AMACR expression have a tendency to present with higher level of PSA and positive bone deposits. A tendency was identified for patients with AMACR score 7 to have higher nadir PSA. Biochemical failure was depicted in 71.4% of patients with AMACR Score 7, while patients with AMACR score less than 7 didn't had biochemical failure. On follow up bone scan, ten patients get progression and the AMACR score in these patients was 7.Conclusion: Our initial results focused on the role of AMACR immune expression as a poor prognostic indicator of prostate cancer, being linked with high Gleason's score, increased incidence of positive bonemetastases and initial high PSA level. In addition, the results highlighted the potential role of AMACR expression as predictive marker of hormonal treatment.